Advertisement

Ischemic Optic Neuropathies: Update

  • Elizabeth M. Palkovacs
  • Karl C. Golnik
Chapter
Part of the Current Practices in Ophthalmology book series (CUPROP)

Abstract

Compromised blood supply to the optic nerve with concurrent ischemic damage is a common cause of optic neuropathy and has many variants. This chapter focuses on this entity and its types. A brief description of the relevant clinical anatomy is included along with a short description of the pertinent points to be considered during history taking and clinical examination of these patients. Nonarteritic anterior ischemic optic neuropathy (NAION), which is the commonest type of ischemic optic neuropathy, is discussed in detail—including clinical features, investigations, and recent advances and trials for the management of this entity. A complete review of arteritic ischemic optic neuropathy—associated with giant cell arteritis (GCA)—is also included including management of the acute episode and long-term management. Less common variants such as posterior ischemic optic neuropathy (PION) are also discussed to provide a complete overview of the topic.

Keywords

Ischemic optic neuropathy Nonarteritic anterior ischemic optic neuropathy (NAION) Giant cell arteritis (GCA) Posterior ischemic optic neuropathy (PION) Diabetic papillopathy 

References

  1. 1.
    Kupfer C, Chumbly L, Downer JC. Quantitative histology of optic nerve tract and lateral geniculate nucleus of man. J Anat. 1967;101:393–401.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Potts AM, Hodges D, Sherman CB, et al. Morphology of the primate optic nerve: I-III. Invest Ophthalmol Vis Sci. 1972;11:980–1016.Google Scholar
  3. 3.
    Hayreh SS. The 1994 Van Sallman Lecture: the optic nervehead circulation in health and disease. Exp Eye Res. 1995;61:259–72.CrossRefGoogle Scholar
  4. 4.
    Onda E, Cioffi GA, Bacon DR, et al. Microvasculature of the human optic nerve. Am J Ophthalmol. 2008;43:308–12.Google Scholar
  5. 5.
    Johnson LN, Arnold AC. Incidence of nonarteritic anterior ischemic optic neuropathy. Population-based study in the state of Missouri and Los Angeles County, California. J Neuroophthalmol. 1994;14:38–44.CrossRefGoogle Scholar
  6. 6.
    Arnold AC, et al. The spectrum of optic disc ischemia in patients younger than 50 years. Trans Am Ophthalmol Soc. 2013;111:93–118.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Hattenhauer MG, Leavitt JA, Hodge DO, et al. Incidence of non-arteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1997;123:103–7.CrossRefGoogle Scholar
  8. 8.
    Hayreh SS, Joos KM, Podhajsky PA, et al. Systemic diseases associated with nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1994;118:766–80.CrossRefGoogle Scholar
  9. 9.
    Jacobson DM, Vierkant RA, Belongia EA. Nonarteritic anterior ischemic optic neuropathy. A case-control study of potential risk factors. Arch Ophthalmol. 1997;115:1403–7.CrossRefGoogle Scholar
  10. 10.
    Ischemic Optic Neuropathy Decompression Trial Study Group. Characteristics of patients with nonarteritic anterior ischemic optic neuropathy eligible for the Ischemic Optic Neuropathy Decompression Trial. Arch Ophthalmol. 1996;114:1366–74.CrossRefGoogle Scholar
  11. 11.
    Hayreh SS, Podhajsky PA, Zimmerman B. Nonarteritic anterior ischemic optic neuropathy: time of onset of visual loss. Am J Ophthalmol. 1997;124:641–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Hayreh SS, Podhajsky P, Zimmerman MB. Role of nocturnal arterial hypotension in optic nerve head ischemic disorders. Ophthalmologica. 1999;213:76–96.CrossRefPubMedGoogle Scholar
  13. 13.
    Doro S, Lessell S. Cup disc ratio and ischemic optic neuropathy. Arch Ophthalmol. 1993;103:1143–4.CrossRefGoogle Scholar
  14. 14.
    Beck RW, Servais GE, Hayreh SS. Anterior ischemic optic neuropathy. IX. Cup to disc ratio and its role in pathogenesis. Ophthalmology. 1987;94:1502–8.CrossRefGoogle Scholar
  15. 15.
    Fry CL, Carter JE, Kanter MC, et al. Anterior ischemic optic neuropathy is not associated with carotid artery atherosclerosis. Stroke. 1993;24:539–42.CrossRefPubMedGoogle Scholar
  16. 16.
    Mojan DS, Hedges TR, Ehrenberg B, et al. Association between sleep apnea syndrome and nonarteritic anterior ischemic optic neuropathy. Arch Ophthalmol. 2002;120:601–5.CrossRefGoogle Scholar
  17. 17.
    Pomeranz HD, Smith KH, Hart WM Jr, et al. Sildenafil-associated nonarteritic anterior ischemic optic neuropathy. Ophthalmology. 2002;109:584–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Campbell UB, et al. Acute nonarteritic anterior ischemic optic neuropathy and exposure to phosphodiesterase type 5 inhibitors. J Sex Med. 2015;12:139–51.CrossRefPubMedGoogle Scholar
  19. 19.
    Fraunfelder FW, Pomeranz HD, Egan RA. Nonarteritic anterior ischemic optic neuropathy and sildenafil. Arch Ophthalmol. 2006;124:733–4.CrossRefPubMedGoogle Scholar
  20. 20.
    Nathoo NA, et al. Association between phosphdiesterase-5 inhibitors and nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol. 2015;35:12–5.CrossRefPubMedGoogle Scholar
  21. 21.
    Repka MX, Savion PJ, Schatz NJ, et al. Clinical profile and long-term implications of anterior ischemic optic neuropathy. Am J Ophthalmol. 1983;96:478–83.CrossRefPubMedGoogle Scholar
  22. 22.
    Swartz NG, Beck RW, Savino PJ, et al. Pain in anterior ischemic optic neuropathy. J Neuroophthalmol. 1995;15:9–10.CrossRefPubMedGoogle Scholar
  23. 23.
    Warner JEA, Lessell S, Rizzo JF, et al. Does optic disc appearance distinguish ischemic optic neuropathy from optic neuritis. Arch Ophthalmol. 1997;115:1408–10.CrossRefPubMedGoogle Scholar
  24. 24.
    Friedland S, Winterkorn JM, Burde RM. Luxury perfusion following anterior ischemic optic neuropathy. J Neuroophthalmol. 1996;16:163–71.CrossRefPubMedGoogle Scholar
  25. 25.
    Arnold AC, Hepler RS. Natural history of non arteritic ischemic optic neuropathy. J Neuroophthalmol. 1994;14:66–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Newman NJ, Scherer R, Langenberg P, et al. The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study. Am J Ophthalmol. 2002;134:317–28.CrossRefPubMedGoogle Scholar
  27. 27.
    Hayreh SS, Zimmerman MB. Nonarteritic anterior ischemic optic neuropathy: clinical characteristics in diabetic patients versus nondiabetic patients. Ophthalmology. 2008;115:1818–25.CrossRefPubMedGoogle Scholar
  28. 28.
    Hayreh SS. Anterior ischemic optic neuropathy. I. Terminology and pathogenesis. Br J Ophthalmol. 1974;58:955–63.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Lessell S. Nonarteritic anterior ischemic optic neuropathy: enigma variations (editorial). Arch Ophthalmol. 1999;117:386–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Arnold AC. Pathogenesis of nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol. 2003;23:157–63.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Galetta SL, Plock GL, Kushner MJ, et al. Ocular thrombosis associated with antiphospholipid antibodies. Ann Ophthalmol. 1991;23:207–12.PubMedGoogle Scholar
  32. 32.
    Knox DL, Hanneken AM, Hollows FC. Uremic optic neuropathy. Arch Ophthalmol. 1988;106:50–4.CrossRefGoogle Scholar
  33. 33.
    The Ischemic Optic Neuropathy Decompression Trial Research Group. Optic nerve decompression surgery for nonarteritic ischemic optic neuropathy (NAION) is not effective and may be harmful. JAMA. 1995;273:625–32.CrossRefGoogle Scholar
  34. 34.
    Arnold AC, Helper RS, Lieber M, et al. Hyperbaric oxygen therapy for nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1996;122:535–41.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Botelho PJ, Johnson LN, Arnold AC. The effect of aspirin on the visual outcome of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1996;121:450–1.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Bennett JL, Thomas S, Olson JL, et al. Treatment of nonarteritic anterior ischemic optic neuropathy with intravitreal bevacizumab. J Neuroopthalmol. 2007;27:238–40.CrossRefGoogle Scholar
  37. 37.
    Kaderli B, Avci R, Yucel A, et al. Intravitreal triamcinolone improves recovery of visual acuity in nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol. 2007;27:164–8.CrossRefGoogle Scholar
  38. 38.
    Kupersmith MJ, Miller NR. A nonarteritic anterior ischemic optic neuropathy clinical trial: an industry and NORDIC collaboration. J Neuroopthalmol. 2016;36(3):235–7.CrossRefGoogle Scholar
  39. 39.
    Regillo CD, Brown GC, Savino PJ, et al. Diabetic papillopathy. Patient characteristics and fundus findings. Arch Ophthalmol. 1995;113:889–95.CrossRefPubMedGoogle Scholar
  40. 40.
    Mansour AM, El-Dairi MA, Shehab MA, et al. Periocular corticosteroids in diabetic papillopathy. Eye. 2005;19:45–51.CrossRefPubMedGoogle Scholar
  41. 41.
    Al-Haddad CE, Jurdi FA, Bashshur ZF. Intravitreal triamcinolone acetonide for the management of diabetic papillopathy. Am J Ophthalmol. 2004;137:1151–3.CrossRefPubMedGoogle Scholar
  42. 42.
    Chew SS, Kerr NM, Danesh-Meyer HV. Giant cell arteritis. J Clin Neurosci. 2009;16:1263–8.CrossRefPubMedGoogle Scholar
  43. 43.
    Goodman BW. Temporal arteritis. Am J Med. 1979;67:839–53.CrossRefPubMedGoogle Scholar
  44. 44.
    Liu NH, LaBree LD, Feldon SE, et al. The epidemiology of giant cell arteritis: a 12 year retrospective study. Ophthalmology. 2001;108:1145–9.CrossRefPubMedGoogle Scholar
  45. 45.
    Brack A, Martinez-Taboada V, Stanson A, Goronzy JJ, Weyand CM. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum. 1999;42:311–7.CrossRefPubMedGoogle Scholar
  46. 46.
    ICHD-II. Available at http://ihs-classification.org/en/.
  47. 47.
    Brass SD, Durand ML, Stone JH, Chen JW, Stone JR. Case records of the Massachusetts General Hospital. Case 36-2008. A 59-year-old man with chronic daily headache. N Engl J Med. 2008;359:2267–78.CrossRefPubMedGoogle Scholar
  48. 48.
    Kattah JC, Mejico L, Chrousos GA, et al. Pathologic findings in steroid responsive optic infarct in giant cell arteritis. Neurology. 1999;53:177–80.CrossRefGoogle Scholar
  49. 49.
    McDonnell PJ, Moore GW, Miller NR, et al. Temporal arteritis. A clinicopathologic study. Ophthalmology. 1986;93:518–30.CrossRefPubMedGoogle Scholar
  50. 50.
    Jonasson F, Cullen JF, Elton RA. Temporal arteritis. A 14-year epidemiological, clinical, and prognositic study. Scott Med J. 1979;24:111–7.CrossRefPubMedGoogle Scholar
  51. 51.
    Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatic and giant cell arteritis. N Engl J Med. 2002;347:261–71.CrossRefGoogle Scholar
  52. 52.
    Simmons RJ, Cogan DG. Occult temporal arteritis. Arch Ophthalmol. 1962;68:8–18.CrossRefPubMedGoogle Scholar
  53. 53.
    Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, et al. Visual manifestations of giant cell arteritis. Trends and clinical spectrum in over 161 patients. Medicine. 2000;79:283–92.CrossRefPubMedGoogle Scholar
  54. 54.
    Hayreh SS, Podhajsky PA, Zimmerman B. Occult giant cell arteritis: ocular manifestations. Am J Ophthalmol. 1998;125:521–6.CrossRefPubMedGoogle Scholar
  55. 55.
    Eshaghian J. Controversies regarding giant cell arteritis. Doc Ophthalmol. 1979;47:43–67.CrossRefPubMedGoogle Scholar
  56. 56.
    Huna-Baron R, Mizrachi IB, Glovinsky Y. Intraocular pressure is low in eyes with giant cell arteritis. J Neuroophthalmol. 2006;26:273–5.CrossRefPubMedGoogle Scholar
  57. 57.
    Barricks ME, Traviesa DB, Glaser JS, et al. Ophthalmoplegia in cranial arteritis. Brain. 1977;100:209–21.CrossRefPubMedGoogle Scholar
  58. 58.
    El-Dairi MA, Chang L, et al. Diagnostic algorithm for patients with suspected giant cell arteritis. J Neuro-Oncol. 2015;35:246–53.Google Scholar
  59. 59.
    Hall JK, Volpe NJ, Galetta SL, Liu GT, Syed NA, Balcer LJ. The role of unilateral temporal artery biopsy. Ophthalmology. 2003;110:543–8.CrossRefPubMedGoogle Scholar
  60. 60.
    Boyev LR, Miller NR, Green WR. Efficacy of unilateral versus bilateral temporal artery biopsies for the diagnosis of giant cell arteritis. Am J Ophthalmol. 1999;128:211–5.CrossRefPubMedGoogle Scholar
  61. 61.
    Miller NR. Giant cell arteritis. J Neuroophthalmol. 2000;20:219–20.CrossRefPubMedGoogle Scholar
  62. 62.
    Lessell S. Bilateral temporal artery biopsies in giant cell arteritis. J Neuroophthalmol. 2000;20:220–1.CrossRefPubMedGoogle Scholar
  63. 63.
    Chambers WA, Bernadino VB. Specimen length in temporal artery biopsies. J Clin Neuroophthalmol. 1988;8:121–5.Google Scholar
  64. 64.
    Jacobson DM, Slamovitz TL. ESR and its relationship to hematocrit in giant cell arteritis. Arch Ophthalmol. 1987;105:965–7.CrossRefPubMedGoogle Scholar
  65. 65.
    Hayreh SS, Podhajsky PA, Raman R, et al. Giant cell arteritis: validity and reliability of various diagnostic criteria. Am J Ophthalmol. 1997;123:285–96.CrossRefPubMedGoogle Scholar
  66. 66.
    Parikh M, Miller NR, Lee AG, et al. Prevalence of a normal C-reactive protein with an elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis. Ophthalmology. 2006;113:1842–5.CrossRefPubMedGoogle Scholar
  67. 67.
    Sadun F, Pece A, Brancato R. Fluorescein and indocyanine green angiography in the diagnosis of giant cell arteritis. Br J Ophthalmol. 1998;82:1344–5.CrossRefPubMedGoogle Scholar
  68. 68.
    Landau K, Savino PJ, Gruber P. Diagnosing giant cell arteritis: is ultrasound enough? J Neuroophthalmol. 2013;33:394–400.CrossRefPubMedGoogle Scholar
  69. 69.
    Chan CC, Paine M, O’Day J. Steroid management in giant cell arteritis. Br J Ophthalmol. 2001;85:1061–4.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Cornblath WT, Eggenberger ER. Progressive vision loss from giant cell arteritis despite high dose intravenous methylprednisolone. Ophthalmology. 1997;104:854–8.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Clearkin LG. IV steroids for central retinal artery occlusion in giant cell arteritis. Ophthalmology. 1992;99:1482–3.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Hayreh SS, Biousse V. Treatment of acute visual loss in giant cell arteritis: should we prescribe high-dose intravenous steroids or just oral steroids? J Neuroophthalmol. 2012;32:278–87.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Hayreh SS, Zimmerman B. Visual deterioration in giant cell arteritis patient while on high doses of corticosteroid therapy. Ophthalmology. 2003;110:1204–15.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Lessell S. Optic neuropathy in giant cell arteritis. J Neuroophthalmol. 2005;25:247.CrossRefGoogle Scholar
  75. 75.
    Kim N, Trobe JD, Flint A, Keoleian G. Late ipsilateral recurrence of ischemic optic neuropathy in giant cell arteritis. J Neuroophthalmol. 2003;23:122–6.CrossRefGoogle Scholar
  76. 76.
    Chan CCK, Paine M, O’Day J. Predictors of recurrent ischemic optic neuropathy in giant cell arteritis. J Neuroophthalmol. 2005;25:14–7.CrossRefGoogle Scholar
  77. 77.
    Weyand CM, Liao YJ, Goronzy JJ. The immunopathology of giant cell arteritis: diagnostic and therapeutic implications. J Neuroophthalmol. 2012;32:259–65.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Liu GT, Glaser IS, SCHatz NJ, et al. Visual morbidity in giant cell arteritis: clinical characteristics and prognosis for vision. Ophthalmology. 1994;101:1779–85.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Rauser M, Rismondo V. Ischemic optic neuropathy during corticosteroid therapy for giant cell arteritis. Arch Ophthalmol. 1995;113:707–8.CrossRefPubMedGoogle Scholar
  80. 80.
    Kupersmith MJ, Speira R, Langer R, Richmond M, Peterson M, Speira H, Mitnick H, Paget S. Visual function and quality of life among patients with giant cell (temporal) arteritis. J Neuroophthalmol. 2001;21:266–73.CrossRefPubMedGoogle Scholar
  81. 81.
    Sadda SR, Nee M, Miller NR, et al. Clinical spectrum of posterior ischemic optic neuropathy. Am J Ophthalmol. 2001;132:743–50.CrossRefPubMedGoogle Scholar
  82. 82.
    Hayreh SS. Posterior ischemic optic neuropathy: clinical features, pathogenesis, and management. Eye. 2004;18:1188–206.CrossRefPubMedGoogle Scholar
  83. 83.
    Gilden DH, Lipton HL, Wolf JS, et al. Two patients with unusual forms of varicella-zoster virus vasculopathy. N Engl J Med. 2002;347:1500–3.CrossRefPubMedGoogle Scholar
  84. 84.
    Harrison EQ. Complications of herpes zoster ophthalmicus. Am J Ophthalmol. 1965;60:1111–4.CrossRefPubMedGoogle Scholar
  85. 85.
    Buono LM, Foroozan R. Perioperative posterior ischemic optic neuropathy: review of the literature. Surv Ophthalmol. 2005;50:15–26.CrossRefPubMedGoogle Scholar
  86. 86.
    Newman NJ. Perioperative vision loss after nonocular surgeries. Am J Ophthalmol. 2008;145:604–10.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Worrell L, Rowe M, Petti G. Amaurosis: a complication of bilateral radical neck dissection. Am J Otolaryngol. 2002;23:56–9.CrossRefPubMedGoogle Scholar
  88. 88.
    Buono LM, Foroozan R, Savino PJ, et al. Posterior ischemic optic neuropathy after hemodialysis. Ophthalmology. 2003;110:1216–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  • Elizabeth M. Palkovacs
    • 1
  • Karl C. Golnik
    • 2
  1. 1.Northern California Kaiser Permanente Medical GroupSouth San FranciscoUSA
  2. 2.University of Cincinnati & the Cincinnati Eye InstituteCincinnatiUSA

Personalised recommendations